Abstract 45P
Background
Pathologic complete response (pCR) is often utilized as a surrogate marker for overall survival in breast cancer. Significant differences in pCR rates are reported in many studies depending on the biological tumor profile and molecular classification. Based on our observations we hypothesize that few breast cancer patients are less likely to achieve pCR after neoadjuvant chemotherapy (NACT). The role of demographic variables in predicting pCR is still not clear. The aim of this study was to evaluate various demographic factors which could impact pCR rates.
Methods
A prospective analysis of 1246 patients with breast carcinoma who had undergone neoadjuvant chemotherapy (NACT) followed by surgery was done from June 2020 to December 2022. Demographic, surgical, and pathological data were collected on completion of therapy. Categorical variables were analyzed using χ2 or Fisher’s exact test and continuous data were analyzed using t-tests. Multiple linear regressions were used to study interactions between various demographic factors and pCR. Statistical analysis was done using SPSS v25.
Results
A total of 1324 patients were offered NACT, of which 1246 (94.1%) who underwent resection post-NACT were included in the analysis. Overall, 275 (22.1%) patients had pCR. 39 (14.2%) in ER+/HER2- group, 131 (47.6%) in HER2+ group; and 105 (38.2%) in ER-/HER2- group had pCR. Univariate analysis showed significant association between age <50 years, low body-mass index, and ability to achieve pCR. However, women with obesity had higher odds of residual disease (OR = 0.191 [0.029-1.157]; p=0.076). The results were consistent even after controlling for confounding variables such as grade, receptor status, and clinical T and N stages.
Conclusions
Younger age can predict a pCR and is an independent prognostic factor for locoregional recurrence in locally advanced breast cancer patients after NACT. Obesity is a risk factor for failure to achieve PCR in women undergoing NACT. The contrary was observed in non-obese patients as they had higher odds of achieving PCR. Studies with larger groups are needed to validate this observation. Further studies evaluating the role of BMI in drug resistance would be valuable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract